Aegis Therapeutics awarded US Patent for stabilized HGH formulations
Anti aging, Body Building, Buy hgh, Guide, HGH products, HGH: Human Growth Hormone, News, Review
Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented or proprietary drug delivery and drug formulation technologies through product-specific licenses. Now the company has been awarded U.S. Patent 7,425,542, titled “Stabilizing alkylglycoside compositions and methods thereof” which provides broad protection for stabilized human growth hormone (HGH) formulations.
Human growth hormone is a recombinant protein drug which like any other protein therapeutics including insulin, erythropoietin, and interferon, is sensitive to heat and agitation and subject to aggregation — a phenomenon that reduces the potency of protein drugs and increases unwanted and sometimes dangerous immunogenicity. As a result, protein therapeutics must be stored and shipped from manufacturer, to the pharmacy, and ultimately to the patient under an uninterrupted chain of refrigerated conditions, referred to as the “cold chain.” If ‘cold chain’ is not properly maintained during shipment, it hampers the effectiveness of protein drugs.
The Aegis ProTek(R) technology has been employed to create stabilized formulations of HGH, insulin, antibodies, and other protein drugs that remain unchanged even after continuous agitation for many weeks or months at elevated temperatures. The patented formulations are suitable for intranasal delivery via a simple metered nasal spray as well as by standard injection or external drug infusion pump. Aegis ProTek(R) technology is expected to provide patients with safer, more convenient, non-injectable delivery options while extending the effective patent life of HGH and other protein drugs.
Popularity: 12% [?]